118 related articles for article (PubMed ID: 38180342)
1. Mutational signature and prognosis in adenocarcinoma of the bladder.
Yang G; Shahatiaili A; Bai S; Wang L; Jin D; Cao M; Su P; Liu Q; Tao K; Long Q; Shi Y; Xiao J; Tian F; Zhang L; Chen H; Su X
J Pathol; 2024 Mar; 262(3):334-346. PubMed ID: 38180342
[TBL] [Abstract][Full Text] [Related]
2. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
3. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
Baker SC; Mason AS; Southgate J
Eur Urol; 2020 Aug; 78(2):143-147. PubMed ID: 32349929
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
5. Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma.
Cai X; Chen Z; Deng M; Li Z; Wu Q; Wei J; Dai C; Wang G; Luo C
Ann Transl Med; 2020 Sep; 8(18):1176. PubMed ID: 33241025
[TBL] [Abstract][Full Text] [Related]
6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
8. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.
Fantini D; Seiler R; Meeks JJ
Urol Oncol; 2019 Nov; 37(11):818-825. PubMed ID: 30446446
[TBL] [Abstract][Full Text] [Related]
9. Genomic case report of a low grade bladder tumor metastasis to lung.
Van Every MJ; Dancik G; Paramesh V; Gurda GT; Meier DR; Cash SE; Richmond CS; Guin S
BMC Urol; 2018 Sep; 18(1):74. PubMed ID: 30176882
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study.
Stohr BA; Chan E; Anderson JA; Matoso A; Murati Amador BI; Cheng L; Osunkoya AO
Hum Pathol; 2022 Nov; 129():98-102. PubMed ID: 36108931
[TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
13. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
Wang R; Song S; Harada K; Ghazanfari Amlashi F; Badgwell B; Pizzi MP; Xu Y; Zhao W; Dong X; Jin J; Wang Y; Scott A; Ma L; Huo L; Vicente D; Blum Murphy M; Shanbhag N; Tatlonghari G; Thomas I; Rogers J; Kobayashi M; Vykoukal J; Estrella JS; Roy-Chowdhuri S; Han G; Zhang S; Mao X; Song X; Zhang J; Gu J; Johnson RL; Calin GA; Peng G; Lee JS; Hanash SM; Futreal A; Wang Z; Wang L; Ajani JA
Gut; 2020 Jan; 69(1):18-31. PubMed ID: 31171626
[TBL] [Abstract][Full Text] [Related]
14. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
Bellamri M; Brandt K; Brown CV; Wu MT; Turesky RJ
Arch Toxicol; 2021 Jun; 95(6):2189-2199. PubMed ID: 33938965
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate.
Jing Y; Zhang R; Ma P; Cai MC; Zhuang G; Chen H
J Pathol; 2018 Jan; 244(1):5-10. PubMed ID: 29023722
[TBL] [Abstract][Full Text] [Related]
17. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer.
Besaratinia A; Bates SE; Pfeifer GP
Cancer Res; 2002 Aug; 62(15):4331-8. PubMed ID: 12154037
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
[TBL] [Abstract][Full Text] [Related]
19. Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA.
Booka E; Tsubosa Y; Yokota T; Mayanagi S; Ishii K; Urakami K; Ohshima K; Ohnami S; Nagashima T; Yamaguchi K
Esophagus; 2021 Oct; 18(4):743-752. PubMed ID: 33826001
[TBL] [Abstract][Full Text] [Related]
20. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
